Warning letter
Innovative Compounding Pharmacy: warning letter of Jun 20, 2016
FDA warning letter 484658 · San Francisco District Office
Key facts
| Reference number | 484658 |
|---|---|
| Company | Innovative Compounding Pharmacy |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Jun 20, 2016 |
| Posted date | Nov 8, 2016 |
| Issuing office | San Francisco District Office |
| Product type | Drugs |
| CFR sections cited | 211.28(a), 211.42(b), 211.42(c)(10)(iv), 211.42(c)(10)(v), 211.42(c)(10)(vi), 211.113(b), 210.1(b), 211.167(a), 201.115, 200.10(b) |
| Inspection city | Folsom |
| Inspection ZIP | 95630 |
| Inspection start date | Apr 13, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: